apo-risperidone risperidone 2 mg tablet blister pack
arrotex pharmaceuticals pty ltd - risperidone, quantity: 2 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; lactose monohydrate; magnesium stearate; hypromellose; maize starch; propylene glycol; purified talc; sodium lauryl sulfate; sunset yellow fcf aluminium lake; titanium dioxide - treatment of schizophrenia and related psychoses.,short term treatment of acute mania associated with bipolar 1 disorder (see dosage and administration: bipolar mania).,treatment of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe demetia of the alzheimer type). *(see dosage and administration: behavioural disturbances in dementia),risperidone is indicated for the treatment *(up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. *(see dosage and administration: behavioural disturbances in dementia),treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data).,treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).
apo-risperidone risperidone 1 mg tablet blister pack
arrotex pharmaceuticals pty ltd - risperidone, quantity: 1 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; colloidal anhydrous silica; magnesium stearate; hypromellose; maize starch; propylene glycol; purified talc; sodium lauryl sulfate - treatment of schizophrenia and related psychoses.,short term treatment of acute mania associated with bipolar 1 disorder (see dosage and administration: bipolar mania).,treatment of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe demetia of the alzheimer type). *(see dosage and administration: behavioural disturbances in dementia),risperidone is indicated for the treatment *(up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. *(see dosage and administration: behavioural disturbances in dementia),treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data).,treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).
apo-risperidone risperidone 0.5 mg tablet blister pack
arrotex pharmaceuticals pty ltd - risperidone, quantity: 0.5 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; lactose monohydrate; hypromellose; iron oxide red; maize starch; propylene glycol; purified talc; sodium lauryl sulfate; titanium dioxide - treatment of schizophrenia and related psychoses.,short term treatment of acute mania associated with bipolar 1 disorder (see dosage and administration: bipolar mania).,treatment of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe demetia of the alzheimer type). *(see dosage and administration: behavioural disturbances in dementia),risperidone is indicated for the treatment *(up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. *(see dosage and administration: behavioural disturbances in dementia),treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data).,treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).
dom-risperidone solution
dominion pharmacal - risperidone (risperidone tartrate) - solution - 1mg - risperidone (risperidone tartrate) 1mg - atypical antipsychotics
jamp-risperidone solution
jamp pharma corporation - risperidone (risperidone tartrate) - solution - 1mg - risperidone (risperidone tartrate) 1mg - atypical antipsychotics
ava-risperidone solution
avanstra inc - risperidone (risperidone tartrate) - solution - 1mg - risperidone (risperidone tartrate) 1mg - atypical antipsychotics
pms-risperidone solution
pharmascience inc - risperidone (risperidone tartrate) - solution - 1mg - risperidone (risperidone tartrate) 1mg - atypical antipsychotics
risperidone- risperidone solution
par pharmaceutical - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 1 mg in 1 ml - risperidone oral solution is indicated for the treatment of schizophrenia. efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see clinical studies (14.1) ]. monotherapy risperidone oral solution is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years) [see clinical studies (14.2) ]. adjunctive therapy risperidone adjunctive therapy with lithium or valproate is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in one short-term trial in adults [see clinical studies (14.3) ]. risperidone oral solution is indicated for the treatment of irritability associated with autistic disorder, including symptoms of aggression towards others, deliberate self-injur
apo-risperidone solution
apotex inc - risperidone (risperidone tartrate) - solution - 1mg - risperidone (risperidone tartrate) 1mg - atypical antipsychotics
risperidone- risperidone tablet
lake erie medical dba quality care products llc - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 1 mg - risperidone tablets are indicated for the treatment of schizophrenia. efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see clinical studies (14.1)] . monotherapy risperidone tablets are indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years)[see clinical studies (14.2)] . adjunctive therapy risperidone tablets adjunctive therapy with lithium or valproate is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in one short-term trial in adults [see clinical studies (14.3)] . risperidone tablets are indicated for the treatment of irritability associated with autistic disorder, including symptoms of aggression towards others, deliberate self-injuriousness, tem